Donald Jensen to Sulfonamides
This is a "connection" page, showing publications Donald Jensen has written about Sulfonamides.
Connection Strength
1.264
-
Glecaprevir/pibrentasvir for the treatment of chronic hepatitis C: design, development, and place in therapy. Drug Des Devel Ther. 2019; 13:2565-2577.
Score: 0.657
-
Daclatasvir plus asunaprevir for HCV genotype 1b infection in patients with or without compensated cirrhosis: a pooled analysis. Liver Int. 2016 07; 36(7):954-62.
Score: 0.129
-
Interferon-free regimens containing setrobuvir for patients with genotype 1 chronic hepatitis C: a randomized, multicenter study. Liver Int. 2016 Apr; 36(4):505-14.
Score: 0.128
-
Pegylated interferon based therapy with second-wave direct-acting antivirals in genotype 1 chronic hepatitis C. Liver Int. 2015 Jan; 35 Suppl 1:11-7.
Score: 0.120
-
Randomized study of danoprevir/ritonavir-based therapy for HCV genotype 1 patients with prior partial or null responses to peginterferon/ribavirin. J Hepatol. 2015 Feb; 62(2):294-302.
Score: 0.117
-
Retreatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin. N Engl J Med. 2014 Apr 24; 370(17):1604-14.
Score: 0.114